Millennium's Chief Scientific Officer Appointed to National Advisory Council for Human Genome Research
CAMBRIDGE, Mass., Feb. 14 /PRNewswire-FirstCall/-- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today announced that Robert I. Tepper, M.D., the company's chief scientific officer and executive vice president, Discovery, has been appointed to the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH).
(Photo: newscom.com )
The National Advisory Council for Human Genome Research works in direct consultation with the Secretary and the Director of the National Human Genome Research Institute (NHGRI). The Council is responsible for advising the Secretary; the Assistant Secretary for Health; the Director, NIH; and the Director, NHGRI, on matters relating to the conduct, support and dissemination of information respecting human genome research, training and other programs related to the human genome initiative. The Council consists of 15 members representing the disciplines of genetics, genomics, molecular biology, biochemistry, chemistry, information science, mathematics, engineering, public health, public policy, health policy, management, law and economics.
``Millennium's commitment to delivering the next era of breakthrough therapeutic products is matched by our commitment to maintaining a socially responsible presence in shaping policy,'' said Mark Levin, chief executive officer at Millennium. ``We at Millennium are delighted that Bob has been invited to join this prestigious group. His expertise, experience and profound understanding of molecular medicine will be a valuable contribution to the Council.''
``The human genome project has tremendous potential to transform medical care as we know it today and its completion was the first major step towards understanding the molecular basis of disease,'' said Dr. Tepper. ``I am honored to be selected to serve on the Council and look forward to working towards transforming medical practices that will hopefully pave the way for personalized medicine.''
Bob Tepper, M.D., joined Millennium in August 1994 and has served in the capacity of chief scientific officer since March 1999. In 2001 Dr. Tepper was appointed to the position of chief scientific officer and executive vice president, Discovery. Previously, he served as Director of the Laboratory of Tumor Biology at Massachusetts General Hospital Cancer Center where he was the recipient of a Lucille P. Markey Biomedical Scholar award. He continues to serve as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital. Bob is also a founder and former member of the Scientific Advisory Board of Cell Genesys Inc. He received an A.B. in biochemistry from Princeton University and an M.D. degree from Harvard Medical School. He completed his residency in medicine at Massachusetts General Hospital where he was Chief Resident.
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company, applies its comprehensive and integrated science and technology platform for the discovery and development of breakthrough therapeutic and predictive medicine products, with a goal of enabling physicians to more closely customize medical treatment by combining knowledge of the genetic basis for disease and the genetic characteristics of patients on a molecular basis. Millennium is primarily focusing its research and development and commercialization activities in four key areas: cardiovascular, oncology, inflammation and metabolic disease. Through the industrialization of its gene-to-patient platform, Millennium is striving to accelerate the process of drug discovery and development. Headquartered in Cambridge, Massachusetts, Millennium currently employs more than 1,800 people.
This press release contains ``forward-looking statements,'' including statements about our growth and future operating results, discovery and development of products, potential acquisitions, strategic alliances and intellectual property. Various risks may cause Millennium's actual results to differ materially, including: adverse results in our drug discovery and clinical development processes; failure to obtain patent protection for our discoveries; commercial limitations imposed by patents owned or controlled by third parties; our dependence upon strategic alliance partners to develop and commercialize products and services based on our work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from our development efforts; and the requirement for substantial funding to conduct research and development and to expand commercialization activities. For a further list and description of the risks and uncertainties we face, see the reports we have filed with the Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Editor's Note: This release is available on Millennium's Web site at: www.millennium.com
Contacts:
Gina Brazier (investor)
(617) 551-3611
Steve Sylven (media)
(617) 551-8984
Millennium Pharmaceuticals, Inc.
SOURCE: Millennium Pharmaceuticals, Inc. |
